Connect Biopharma Holdings (CNTB) Non-Current Deffered Revenue (2023 - 2024)
Connect Biopharma Holdings (CNTB) posted quarterly Non-Current Deffered Revenue of $632000.0 for Q4 2024, up 56.05% year-on-year from $405000.0 in Q1 2024, and up 56.05% on a QoQ basis from $405000.0 in Q4 2023.
Connect Biopharma Holdings (CNTB) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Non-Current Deffered Revenue for 2 consecutive years, with $632000.0 the latest figure, recorded in Q4 2024.
- Quarterly Non-Current Deffered Revenue rose 56.05% year-over-year to $632000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $632000.0 (up 56.05% YoY) and the FY2024 annual result came in at $632000.0, up 56.05% from the prior year.
- Non-Current Deffered Revenue rose to $632000.0 in Q4 2024 per CNTB's latest filing, from $405000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for CNTB reached as high as $632000.0 in Q4 2024 and fell as low as $405000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | - |
| 10 | Connect Biopharma Holdings | 121.01 Mn | 121.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 632,000.00 |
| Dec 31, 2023 | 405,000.00 |